Svirydenka, Hanna
Muehlematter, Urs J.
Nagel, Hannes W.
Delso, Gaspar
Ferraro, Daniela A.
Kudura, Ken
Burger, Irene A.
ter Voert, Edwin E. G. W. http://orcid.org/0000-0001-8877-338X
Funding for this research was provided by:
GE Healthcare
Article History
Received: 12 August 2019
Revised: 3 December 2019
Accepted: 22 January 2020
First Online: 14 February 2020
Compliance with ethical standards
:
: The scientific guarantor of this publication is I.A. Burger.
: This research was performed at the Department of Nuclear Medicine of the University Hospital Zurich which holds an institutional Research Contract with GE Healthcare. Author G. Delso is employed by GE Healthcare. Author I.A. Burger has received research grants and speaker honoraria from GE Healthcare. The other authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: No complex statistical methods were necessary for this paper.
: All patients included gave written informed general consent for retrospective analysis of their data.
: This retrospective study has been approved by the cantonal ethics committee (BASEC-Nr. 2016-02230).
: Some study subjects or cohorts could have been previously reported in one of our other (unrelated) studies about, e.g., <sup>68</sup>Ga-PSMA-11 and PETMR like:Rupp NJ, Umbricht CA, Pizzuto DA et al (2019) First clinico-pathological evidence of a non PSMA-related uptake mechanism for (68)Ga-PSMA-11 in salivary glands. Journal of Nuclear Medicine. ExternalRef removedMuller J, Ferraro DA, Muehlematter UJ et al (2019) Clinical impact of (68)Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. European Journal of Nuclear Medicine and Molecular Imaging 46:889-900Burger IA, Muller J, Donati OF et al (2019) (68)Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU. Journal of Nuclear Medicine 60:1118-1123Ter Voert EEGV, Muehlematter UJ, Delso G et al (2018) Quantitative performance and optimal regularization parameter in block sequential regularized expectation maximization reconstructions in clinical (68)Ga-PSMA PET/MR. EJNMMI Res 8:70Pizzuto DA, Muller J, Muhlematter U et al (2018) The central zone has increased (68)Ga-PSMA-11 uptake: “Mickey Mouse ears” can be hot on (68)Ga-PSMA-11 PET. European Journal of Nuclear Medicine and Molecular Imaging 45:1335-1343Muehlematter UJ, Rupp NJ, Mueller J, Eberli D, Burger IA (2018) 68Ga-PSMA PET/MR-Positive, Histopathology-Proven Prostate Cancer in a Patient With Negative Multiparametric Prostate MRI. Clinical Nuclear Medicine 43:e282-e284Kranzbuhler B, Nagel H, Becker AS et al (2018) Clinical performance of (68)Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging 45:20-30
: • Retrospective• Experimental• Performed at one institution